Quick Answer
Sunshine Biopharma Inc. reported Operating Income of -$5.81 million for fiscal year 2024.
Sunshine Biopharma Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2024 | -$5.81M | -21.5% |
| 2023 | -$4.79M | +82.3% |
| 2022 | -$27.00M | -1006.5% |
| 2021 | -$2.44M | -323.0% |
| 2020 | -$576.9K | +10.1% |
| 2019 | -$641.6K | +44.9% |
| 2018 | -$1.16M | -35.8% |
| 2017 | -$857.2K | +13.7% |
| 2016 | -$993.1K | -27.3% |
| 2015 | -$780.3K | +55.5% |
| 2014 | -$1.76M | +9.3% |
| 2013 | -$1.94M | -174.0% |
| 2012 | -$706.7K | -27.1% |
| 2011 | -$556.2K | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.09M | +1.8% | +47.1% |
| June 30, 2025 | -$2.05M | -62.0% | -58.6% |
| March 31, 2025 | -$1.30M | +4.1% | -17.1% |
| September 30, 2024 | -$1.11M | -41.9% | +12.8% |
| June 30, 2024 | -$1.27M | -25.1% | +6.1% |
| March 31, 2024 | -$1.35M | +26.2% | -73.3% |
| September 30, 2023 | -$779.5K | +54.6% | +23.1% |
| June 30, 2023 | -$1.01M | -45.7% | +44.6% |
- Sunshine Biopharma Inc. showed a decrease of -21.5% in Operating Income compared to the prior fiscal year.
- Over the 2011–2024 period, Sunshine Biopharma Inc.’s operating income has declined by 945.0% (from -$556.2 thousand to -$5.81 million).
- The most recent figure is from Sunshine Biopharma Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on April 1, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: